1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Market Report, "Lithuania Pharmaceuticals & Healthcare Report Q3 2011", published

Recently published research from Business Monitor International, "Lithuania Pharmaceuticals & Healthcare Report Q3 2011", is now available at Fast Market Research

 
PRLog - Jul. 18, 2011 - BMI View: Despite a more positive economic outlook, Lithuania is still considered one of the less attractive pharmaceutical markets within Central and Eastern Europe (CEE). Factors such as difficult economic conditions and falling population numbers will continue to constrain value growth with regard to pharmaceutical spending, especially given the fact that the authorities are actively pursuing costcontainment measures. On the other hand, the strength of its local drug manufacturing industry will continue to underpin export opportunities.

Headline Expenditure Projections

* Pharmaceuticals: LTL1.57bn (US$601mn) in 2010 to LTL1.59bn (US$660mn) in 2011; +1.6% in local currency terms and +9.8% in US dollar terms. Forecast up significantly from Q211 due to macroeconomic factors and analyst input.
* Healthcare: LTL7.40bn (US$2.83bn) in 2010 to LTL7.80bn (US$3.23bn) in 2011; +5.5% in local currency terms and +14.0% in US dollar terms. US dollar forecast up significantly from Q211 due to exchange rate factors.
* Medical devices: LTL502mn (US$192mn) in 2010 to LTL539mn (US$223mn) in 2011; +7.4% in local currency terms and +16.1% in US dollar terms. Forecast up slightly from Q211 due to macroeconomic factors.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/208368_lithuania_pharmaceutica...
------------------------------------------------------------


Business Environment Rating: In our latest Pharmaceuticals & Healthcare Business Environment Ratings (BER) matrix for Emerging Europe, Lithuania remains in 15th position, out of the 20 markets surveyed. Globally, Lithuania is also found in the bottom half of the table, placing 51st out of the 83 countries we survey for the BER rankings. We expect Lithuania to continue representing one of the less attractive pharmaceutical markets, especially in the light of the need for cost-containment and fiscal discipline, with its matrix ranking unlikely to show dramatic improvements.

Key Trends & Developments

* As anticipated, in May 2011, Valeant Pharmaceuticals, one of Canada's largest pharmaceutical firms, agreed to buy Lithuanian major Sanitas. While Sanitas has recovered a lot of lost ground since the beginning of 2009, the company had not seen a return to its lofty pre-economic-crisis valuation. The premium Valeant is prepared to pay is a clear indication that it will use Sanitas as a tool to enter Russia, adding to the Canadian drugmaker's already considerable presence in Central and Eastern Europe (CEE).
* Recently released official data has revealed that the extent of the reduction in the consumption of branded pharmaceuticals in the country supports our pessimistic outlook for growth, but also highlighted classes of medicine (namely those associated with treatments of certain chronic diseases) set to outperform in this challenging market. The number of branded packages of medicine sold declined by 15.3%, from 82.03mn in 2009 to 69.45mn in 2010.


BMI Economic View: While Lithuania's economy is a long way from pre-crisis levels, the acceleration in growth recorded in Q111 suggests that a gradual recovery is currently underway. However, the economy still has a long way to go in making up lost ground, in what is expected to be a long and painful process. Such a challenging environment is unlikely to be conducive to dynamic growth in the country's pharmaceutical and healthcare expenditure over the short-to-medium term at least.

BMI Political View: Given only a mild economic recovery that followed GDP contractions, policymakers are unlikely to pour much money into the expansion of healthcare provision. On the other hand, we do not see reductions in public and social budgets as being on the cards, given the prevailing political climate and elevated unemployment rates.

Partial Table of Contents:

SWOT Analysis
- Lithuania Pharmaceuticals And Healthcare Industry SWOT
- Lithuania Political SWOT
- Lithuania Economic SWOT
- Lithuania Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Emerging Europe Pharmaceutical Business Environment Ratings, Q311
- Rewards
- Risks
Lithuania - Market Summary
Regulatory Regime
- Baltic Collaboration
- Intellectual Property Developments
- Pricing Regime
- Recent Pricing Developments
- Table: Lithuania - Wholesale Mark-Ups for Reimbursed and Non-Reimbursed Medicines
- Table: Lithuania - Retail Mark-Ups for Reimbursed and Non-Reimbursed Medicines
- Reimbursement Regime
- Recent Reimbursement Developments
Industry Developments
- Epidemiology
- Healthcare System
- Healthcare Insurance
- Biotechnology
- Leading Biotechnology Players
- Clinical Trials
- Table: Lithuania - Applications to Conduct Clinical Trials by Phase (as % of Total)
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Lithuania - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Devices Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Sector
- Domestic Industry
- Table: Drugmakers, Distributors And Retailers Active In The Baltic States, Q207
- Pharmaceutical Wholesale
- Pharmaceutical Retail
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=2083...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Health, Medical, Research
Tags:drug, pharmaceutical, Healthcare, weak, dollar, currency, medicines, austerity
Shortcut:prlog.org/11588132
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share